Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 8/20 | 0.44 |
| ▸ | CETP | P11597 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 4/20 | 0.40 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9637838 | 0.99 | USP2 (0.47) | USP2TLR2CETPCNR1CNR2 | |
| SCHEMBL385333 | 0.99 | USP2 (0.47) | USP2TLR2CETPCNR1CNR2 | |
| SCHEMBL15070695 | 0.99 | USP2 (0.47) | USP2TLR2CETPCNR1CNR2 | |
| SCHEMBL25077516 | 0.99 | USP2 (0.47) | USP2TLR2CETPCNR1CNR2 | |
| SCHEMBL1096268 | 0.99 | USP2 (0.47) | USP2TLR2CETPCNR1CNR2 | |
| SCHEMBL25227181 | 0.99 | USP2 (0.47) | USP2TLR2CETPCNR1CNR2 | |
| SCHEMBL9470027 | 0.99 | USP2 (0.47) | USP2TLR2CETPCNR1CNR2 | |
| SCHEMBL25227184 | 0.99 | USP2 (0.47) | USP2TLR2CETPCNR1CNR2 | |
| SCHEMBL10043031 | 0.99 | USP2 (0.47) | USP2TLR2CETPCNR1CNR2 | |
| SCHEMBL3283279 | 0.99 | USP2 (0.47) | USP2TLR2CETPCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172631-A1 | PHOSPHATIDYL OLIGOGLYCEROLS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) | 2012-07-05 | — | — | US | disclosed |
| US-8076520-B2 | Phosphatidyl oligoglycerols | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20100280282-A1 | PHOSPHATIDYL OLIGOGLYCEROLS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2010-11-04 | — | — | US | disclosed |
| US-7709464-B2 | Phosphatidyl oligoglycerols | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20090035358-A1 | PHOSPHATIDYL OLIGOGLYCEROLS | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2009-02-05 | — | — | US | disclosed |
| US-7351428-B2 | Phosphatidyl oligoglycerols | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2008-04-01 | — | — | US | disclosed |
| US-20040213836-A1 | Phosphatidyl oligoglycerols | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2004-10-28 | — | — | US | disclosed |
| US-20030053978-A1 | Phosphatidyl oligoglycerols | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. | 2003-03-20 | — | — | US | disclosed |
| US-20020090383-A1 | Compounds which increase the survival duration of liposomes | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2002-07-11 | — | — | US | disclosed |
| US-6413543-B1 | DRUG DELIVERY | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2002-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040213836-A1 | Phosphatidyl oligoglycerols | PHOSPHO1, SGMS1, SGMS2 | USP2 2036/4885TLR2 1775/4885CETP 120/4885 |
| US-20030053978-A1 | Phosphatidyl oligoglycerols | PHOSPHO1, SGMS1, SGMS2 | USP2 2339/4885TLR2 2025/4885CETP 150/4885 |
| US-20020090383-A1 | Compounds which increase the survival duration of liposomes | VEGFA, MCL1, LIPA | USP2 1898/4885TLR2 2810/4885CETP 76/4885 |
| US-20100280282-A1 | PHOSPHATIDYL OLIGOGLYCEROLS | PHOSPHO1, SGMS2, LIPG | USP2 2163/4885TLR2 1912/4885CETP 114/4885 |
| US-20120172631-A1 | PHOSPHATIDYL OLIGOGLYCEROLS | PHOSPHO1, SGMS2, LIPG | USP2 2163/4885TLR2 1912/4885CETP 114/4885 |
| US-20090035358-A1 | PHOSPHATIDYL OLIGOGLYCEROLS | PHOSPHO1, SGMS2, LIPG | USP2 2163/4885TLR2 1912/4885CETP 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.